文献速递淋巴瘤

维奈克拉联合奥妥珠单抗治疗初治及复发难治慢性淋巴细胞白血病的1b期研究

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
PubMed 文献 · Blood · 2019-03-12

这项单臂、开放标签1b期研究评估维奈克拉联合奥妥珠单抗在复发难治或初治慢性淋巴细胞白血病中的最大耐受剂量、安全性和耐受性。50例复发难治和32例初治患者入组,未观察到剂量限制性毒性,最常见3-4级不良事件为中性粒细胞减少,总最佳缓解率分别为95%和100%,外周血不可检测微小残留病率分别为64%和91%。

要点

  • 未观察到剂量限制性毒性,两种给药顺序的实验室肿瘤溶解综合征各2例,无临床肿瘤溶解综合征。
  • 最常见3-4级不良事件为中性粒细胞减少(复发难治58%,初治53%)。
  • 总最佳缓解率复发难治95%、初治100%;外周血不可检测微小残留病率分别为64%和91%。

核心结论

  • 维奈克拉联合奥妥珠单抗方案具有可接受的安全性,并可产生持久缓解和高比例的外周血不可检测微小残留病。

研究设计与样本

  • 单臂、开放标签1b期研究,采用3+3设计在100-400 mg范围内递增维奈克拉剂量以确定与标准剂量奥妥珠单抗联合的最大耐受剂量。
  • 患者先接受维奈克拉(方案A)或奥妥珠单抗(方案B)以比较安全性并确定扩展阶段的剂量和方案。
  • 共入组50例复发难治和32例初治慢性淋巴细胞白血病患者;维奈克拉-奥妥珠单抗治疗6个周期,后续维奈克拉单药治疗至疾病进展(复发难治)或固定1年疗程(初治)。
  • 试验注册号为NCT01685892。

主要发现

  • 未观察到剂量限制性毒性。
  • 安全性(包括肿瘤溶解综合征发生率)在两种方案间无差异,每种方案各有2例实验室肿瘤溶解综合征。
  • 选择方案B和维奈克拉400 mg剂量进入扩展阶段。
  • 最常见的3-4级不良事件为中性粒细胞减少,复发难治组为58%的患者,初治组为53%。
  • 3-4级感染发生率复发难治组为29%,初治组为13%;初治组无致死性感染。

关键数值与推荐

  • 维奈克拉剂量在100-400 mg范围内递增,联合标准剂量奥妥珠单抗。
  • 选择方案B(先给奥妥珠单抗)和维奈克拉400 mg剂量进入扩展阶段。
  • 维奈克拉-奥妥珠单抗治疗6个周期,后续维奈克拉单药治疗至疾病进展(复发难治)或固定1年疗程(初治)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This single-arm, open-label, phase 1b study evaluated the maximum tolerated dose (MTD) of venetoclax when given with obinutuzumab and its safety and tolerability in patients with relapsed/refractory (R/R) or previously untreated (first line [1L]) chronic lymphocytic leukemia (CLL). Venetoclax dose initially was escalated (100-400 mg) in a 3 + 3 design to define MTD combined with standard-dose obinutuzumab. Patients received venetoclax (schedule A) or obinutuzumab (schedule B) first to compare safety and determine dose/schedule for expansion. Venetoclax-obinutuzumab was administered for 6 cycles, followed by venetoclax monotherapy until disease progression (R/R) or fixed duration 1-year treatment (1L). Fifty R/R and 32 1L patients were enrolled. No dose-limiting toxicities were observed. Safety, including incidence of tumor lysis syndrome (TLS), did not differ between schedules (2 laboratory TLSs per schedule). Schedule B and a 400-mg dose of venetoclax were chosen for expansion. The most common grade 3-4 adverse event was neutropenia (R/R, 58% of patients; 1L, 53%). Rates of grade 3-4 infections were 29% (R/R) and 13% (1L); no fatal infections occurred in 1L. All infusion-related reactions were grade 1-2, except for 2 grade 3 events. No clinical TLS was observed. Overall best response rate was 95% in R/R (complete response [CR]/CR with incomplete marrow recovery [CRi], 37%) and 100% in 1L (CR/CRi, 78%) patients. Rate of undetectable (<10-4) minimal residual disease (uMRD) in peripheral blood for R/R and 1L patients, respectively, was 64% and 91% ≥3 months after last obinutuzumab dose. Venetoclax and obinutuzumab therapy had an acceptable safety profile and elicited durable responses and high rates of uMRD. This trial was registered at www.clinicaltrials.gov as #NCT01685892.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Flinn IW, Gribben JG, Dyer MJS, et al. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019. PMID: 30862645. doi:10.1182/blood-2019-01-896290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。